Adverse effects (non‐serious) · participants with hidradenitis suppurativa
Topical clindamycin showed no clear difference in adverse effects (non‐serious) compared with placebo (moderate certainty).
1 finding from 1 review
Frequency of serious adverse effects · participants with hidradenitis suppurativa
Adalimumab weekly showed no clear difference in frequency of serious adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Frequency of serious adverse effects · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in frequency of serious adverse effects compared with placebo (high certainty).
1 finding from 1 review
Intervention not reported
Frequency of serious adverse effects 20 to 24 weeks · participants with moderate and severe acne
It is very uncertain whether the intervention changes frequency of serious adverse effects 20 to 24 weeks (very low certainty).
1 finding from 1 review
Number of participants reporting non‐serious adverse effects · participants with hidradenitis suppurativa
Ethinyloestradiol and cyproterone acetate probably leads to lower number of participants reporting non‐serious adverse effects compared with ethinyloestradiol and norgestrel (moderate certainty).
1 finding from 1 review
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
Guselkumab showed no clear difference in proportion of participants with adverse effects serious or severe… compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
Secukinumab probably leads to higher proportion of participants with adverse effects serious or severe… compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Fexofenadine 120 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (1‐week intervention) (moderate certainty).
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Loratadine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).
1 finding from 1 review
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · children with eczema
Cetirizine 0.5 mg/kg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (18‐month intervention) (moderate certainty).
1 finding from 1 review